Clincosm LogoSign in Get a demo

Ciprofloxacin Utilization and Adverse Events Occurrence in Community Pharmacy Setting

Sponsor
Damanhour University (Other)
Overall Status
Completed
CT.gov ID
NCT05916105
Collaborator
(none)
151
Enrollment
1
Location
5.9
Actual Duration (Months)
25.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Background: Ciprofloxacin is a fluoroquinolone that is commonly used to treat a variety of diseases. Ciprofloxacin resistance is rising, resulting in suboptimal patient care. The goal of this study was to evaluate ciprofloxacin use in the community in terms of acceptable prescription, dose, frequency, and duration of use.

Methods: A cross-sectional research was done in Egyptian community pharmacies by community pharmacists. Patients who were administered oral ciprofloxacin during the research period were included.

Condition or Disease Intervention/Treatment Phase
  • Drug: Ciprofloxacin Tablets

Detailed Description

From September 2021 to February 2022, a cross-sectional, research was undertaken to evaluate ciprofloxacin usage. The investigation was carried out by community pharmacists in seven Egyptian community pharmacies.

Data Collection: data gathered from pharmacy patients' records on a data collection form that included the factors indicated. The General Symptoms Questionnaire, physical examination, and blood testing were used to identify adverse occurrences.

Study variables:

  • age, gender, pregnancy/lactation

  • Department/indication

  • Dose, Frequency, Duration, Adverse events, Drug interactions.

Data was categorized and analyzed using appropriate software.

Study Design

Study Type:
Observational
Actual Enrollment :
151 participants
Observational Model:
Other
Time Perspective:
Retrospective
Official Title:
Drug Utilization Evaluation Study of Ciprofloxacin Utilization and Adverse Events Occurrence in Community Pharmacy Setting: A Cross-Sectional Study
Actual Study Start Date :
Sep 1, 2021
Actual Primary Completion Date :
Feb 28, 2022
Actual Study Completion Date :
Mar 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Ciprofloxacin

151 record of Ciprofloxacin

Drug: Ciprofloxacin Tablets
Ciprofloxacin antibiotic
Other Names:
  • Ciprofloxacin

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Indications [6 months]

      Appropriate Indications of ciprofloxacin (frequency )

    2. ciprofloxacin prescription (frequency ) [6 months]

      Number of appropriate ciprofloxacin prescription

    3. adverse events [6 months]

      adverse events occured during ciprofloxacin therapy (frequency )

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • All ciprofloxacin included prescription during the study period.
    Exclusion Criteria:
    • un included ciprofloxacin prescription.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Rehab Hussein Werida Damanhūr Elbehairah Egypt 31527

    Sponsors and Collaborators

    • Damanhour University

    Investigators

    • Study Director: Rehab H Werida, Ass. Prof., Damanhour University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Rehab Werida, Principal Investigator, Damanhour University
    ClinicalTrials.gov Identifier:
    NCT05916105
    Other Study ID Numbers:
    • Ciprofloxacin Utilization
    First Posted:
    Jun 23, 2023
    Last Update Posted:
    Jun 23, 2023
    Last Verified:
    Jun 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Rehab Werida, Principal Investigator, Damanhour University
    Ciprofloxacin
    Use evaluation
    Drug interaction
    Additional relevant MeSH terms:
    Ciprofloxacin

    Study Results

    No Results Posted as of Jun 23, 2023